Biological markers in the diagnosis and treatment of ALS

Journal of the Neurological Sciences

Volumn 165, Issue SUPPL. 1, 1999, Pages

  Kalra, S ^a   Arnold, D L ^a   Cashman, N R ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amyotrophic lateral sclerosis; Positron emission tomography; Survival

Indexed keywords

2 AMINO 3 METHYLAMINOPROPIONIC ACID; 3 OXALYLAMINOALANINE; BIOLOGICAL MARKER; CREATINE; DOMOIC ACID; GLUTAMIC ACID; MESSENGER RNA; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RADIOISOTOPE; REACTIVE OXYGEN METABOLITE; RILUZOLE; ZIDOVUDINE;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DISEASE COURSE; ELECTROMYOGRAPHY; HUMAN; LUNG FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AMYOTROPHIC LATERAL SCLEROSIS; ASPARTIC ACID; BIOLOGICAL MARKERS; BRAIN; CREATINE; DISEASE PROGRESSION; ELECTROMYOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; MONITORING, PHYSIOLOGIC; NEUROPROTECTIVE AGENTS; RILUZOLE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032788061     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00023-4     Document Type: Conference Paper

References (78)

1. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993;16:125-31.
2. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996;47(Suppl 4):221-7.
3. Rothstein ID. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
4. Rothstein JD, Tsai G, Kuncl RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
5. Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995;4:209-16.
6. Gredal O, Pakkenberg B, Nielsen M. Muscarinic, N-methyl-D-aspartate (NMDA) and benzodiazepine receptor binding sites in cortical membranes from amyotrophic lateral sclerosis patients. J Neurol Sci 1996;143:121-5.
7. Virgo L, de BJ. Induction of the immediate early gene c-jun in human spinal cord in amyotrophic lateral sclerosis with concomitant loss of NMDA receptor NR-1 and glycine transporter mRNA. Brain Res 1995;676:196-204.
8. Rothstein JD, Martin U, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Eng J Med 1992;326:1464-8.
9. Rothstein JD, Van Kammen M, Levey AI, Martin U, Kunel RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
10. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Nat Acad Sci USA 1993;90:6591-5.
11. Rothstein JD, Dykes-Hoberg M, Pardo CA et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-86.
12. Ziemann U, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997;49:1292-8.
13. Mills KR, Nithi KA. Corticomotor threshold is reduced in early sporadic amyotrophic lateral sclerosis. Mus Nerv 1997;20:1137-41.
14. Awiszus F, Feistner H. Comparison of single motor unit responses to transcranial magnetic and peroneal nerve stimulation in the tibialis anterior muscle of patients with amyotrophic lateral sclerosis. Electroenceph Clin Neurophysiol 1995;97:90-5.
15. Ludolph AC, Spencer P. Toxic models of upper motor neuron disease. J Neurol Sci 1996;139(Suppl):53-9.
16. Allen CN, Omelchenko I, Ross SM, Spencer P. The neurotoxin, beta-N-methylamino-L-alanine (BMAA) interacts with the strychnine-insensitive glycine modulatory site of the N-methyl-D-aspartate receptor. Neuropharmacology 1995;34:651-8.
17. Teitelbaum JS, Zatorre RI, Carpenter S, Gendron D, Cashman NR. Neurological sequelae of domoic acid intoxication due to ingestion of mussels from Prince Edward Island. New Eng J Med 1990;322:1781-7.
18. Deng HX, Hentati A, Tainer JA et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 1993;261:1047-51.
19. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis [published erratum appears in Nature 1993;364(6435):362]. Nature 1993;362:59-62.
20. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994;264(5166):1772-5.
21. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-74.
22. Hall ED, Andrus PK, Oostveen JA, Fleck TJ, Gurney ME. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998;53:66-77.
23. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 1997;42:326-34.
24. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997;244(Suppl 2):S3-14.
25. Beal MF. Mitochondrial dysfunction and oxidative damage in neurodegenerative diseases, Austin TX: R.G. Landes Company, 1995.
26. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-57.
27. Gurney ME, Liu R, Althaus JS, Hall ED, Becker DA. Mutant CuZn superoxide dismutase in motor neuron disease. J Inherit Metab Dis 1998;2:587-97.
28. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J Med 1994;330:585-91.
29. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-31.
30. Miller RG, Moore D, Young LA et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996;47:1383-8.
31. Andres PL, Skerry LM, Thornell B, Portney LG, Finison U, Munsat TL. A comparison of three measures of disease progression in ALS. J Neurol Sci 1996;139(Suppl):64-70.
32. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II study group. Arch Neurol 1996;53:141-7.
33. Appel V, Stewart SS, Smith G, Appel SLI. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-33.
34. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30.
35. Dantes MI, McComas A. The extent and time course of motor neuron involvement in amyotrophic lateral sclerosis. Mus Nerv 1991;14:416-21.
36. Eisen A, Entezari-Taher MI, Stewart H. Cortical projections to spinal motoneurons: changes with aging and amyotrophic lateral sclerosis. Neurology 1996;46:1396-404.
37. Claus D, Brunholzl C, Kerling FP, Henschel S. Transcranial magnetic stimulation as a diagnostic and prognostic test in amyotrophic lateral sclerosis. J Neurol Sci 1995;129(Suppl):30-4.
38. Cheung G, Gawel MJ, Cooper PW, Farb RI, Ang LC, Gawal MJ. Amyotrophic lateral sclerosis: correlation of clinical and MR imaging findings. Radiology 1995;194:263-70.
39. Mirowitz S, Sartor K, Gado MI, Torack R. Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathologic findings. Radiology 1989;172:535-9.
40. Segawa F. MR findings of the pyramidal tract in amyotrophic lateral sclerosis. Rinsho Shinkeigaku-Clin Neurol 1993;33:835-44.
41. Udaka F, Sawada H, Seriu N, Shindou K, Nishitani N, Kameyama MI. MRI and SPECT findings in amyotrophic lateral sclerosis. Demonstration of upper motor neurone involvement by clinical neuroimaging. Neuroradiology 1992;34:389-93.
42. Yagishita A. MR imaging of the brain of amyotrophic lateral sclerosis. Rinsho Shinkeigaku-Clin Neurol 1995;35:1554-6.
43. Oba H, Araki T, Ohtomo K et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993;189:843-6.
44. Kew JJ, Brooks DJ, Passingham RE, Rothwell JC, Frackowiak RS, Leigh PN. Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. Neurology 1994;44:1101-10.
45. Abe K, Yorifuji S, Nishikawa Y Reduced isotope uptake restricted to the motor area in patients with amyotrophic lateral sclerosis. Neuroradiology 1993;35:410-1.
46. Kato Y, Matsumura K, Kinosada Y, NaritaY, Kuzuhara S, Nakagawa T. Detection of pyramidal tract lesions in ALS by using magnetization-transfer measurements [abstract]. Neurology 1997;48(Suppl. 2):128.
47. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984;43:1136-42.
48. Moffett JR, Namboodiri MA, Cangro C, Neale BJH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131-4.
49. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetylaspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
50. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979;184:539-46.
51. Truckenmiller ME, Namboodiri MA, Brownstein MJ, Neale JH. N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme. J Neurochem 1985;45:1658-62.
52. Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990;85:1427-35.
53. Lee JH, Arcinue E, Ross BD. Brief report: organic osmolytes in the brain of an infant with hypernatremia. N Eng J Med 1994;331:439-42.
54. +. J Neurochem 1994;62:2349-55.
55. Clarke DD, Greenfield S, Dicker E, Tirri U, Ronan EJ. A relationship of N-acetylaspartate biosynthesis to neuronal protein synthesis. J Neurochem 1975;24:479-85.
56. D'Adamo AJ, Gidez LI, Yatsu FM. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp Brain Res 1968;5:267-73.
57. Cangro CB, Namboodiri MA, Sklar LA, Corigliano-Murphy A, Neale JH. Immunohistochemistry and biosynthesis of N-acetylaspartylglutamate in spinal sensory ganglia. J Neurochem 1987;49:1579-88.
58. Pioro EP, Antel JP, Cashman NR, Arnold DL. Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 1994;44:1933-8.
59. Kalra S, Genge A, Cashman N, Antel JP, Arnold DL. Monitoring benefit to upper motor neurons from riluzole therapy in ALS using proton magnetic resonance spectroscopic imaging [abstract]. Neurology 1997;48(Suppl 2):129.
60. Wolfgang B, Karitzky J et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease. Subgroup analysis and follow-up measurements. Arch Neurol 1998;55:931-6.
61. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy. Mag Res Med 1989;9:126-31.
62. Menon DK, Baudouin CJ, Tomlinson D, Hoyle C. Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comp Ass Tomog 1990;14:882-5.
63. Dunlop DS, Mc Hale DM, Lajtha A. Decreased brain N-acetylaspartate in Huntington's disease. Brain Res 1992;580:44-8.
64. Matthews PM, Andermann F, Silver K, Karpati G, Arnold DL. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology 1993;43:2484-90.
65. Cendes F, Andermann F, Preul MC, Arnold DL. Lateralization of temporal lobe epilepsy based on regional metabolic abnormalities in proton magnetic resonance spectroscopic images. Ann Neurol 1994;35:211-6.
66. Arnold DL, Shoubridge EA, Villemure JG, Feindel W. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo. Preliminary observations on tumor grading. NMR Biomed 1990;3:184-9.
67. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Mag Res Med 1995;34:721-7.
68. Davie CA, Hawkins CP, Barker GJ et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
69. Videen JS, Michaelis T, Pinto P, Ross BD. Human cerebral osmolytes during chronic hyponatremia. A proton magnetic resonance spectroscopy study. J Clin Invest 1995;95:788-93.
70. Uno MI, Ueda S, Hondo H, Matsumoto K, Harada MI. Effectiveness of revascularization surgery evaluated by proton magnetic resonance spectroscopy and single photon emission computed tomography. Neurol Med-Chir 1996;36:560-6.
71. Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997;49:1525-33.
72. Schinder AF, Olson EC, Spitzer NC, Montal MI. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996;16:6125-33.
73. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J Neurosci 1996;16:5688-97.
74. Budd SL, Nicholls DG. Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996;67:2282-91.
75. Kalra S, Cashman N, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757-61.
76. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(Suppl. 4):233-41.
77. Karpati G, Carpenter S, Durham H. A hypothesis for the pathogenesis of amyotrophic lateral sclerosis. Rev Neurol 1988;144:672-5.
78. Bates TE, Strangward MI, Keelan J, Davey GI, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 1996;7:1397-400.